PMID- 31456190
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20211204
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 1152
DP  - 2019
TI  - Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and Its 
      Partners to Overcome Metastasis and Drug Resistance.
PG  - 283-292
LID - 10.1007/978-3-030-20301-6_15 [doi]
AB  - Based on the insights gleaned from decades of research, it seems clear that 
      mechanistic target of rapamycin (mTOR) is an essential signaling node that 
      integrates environmental clues for regulation of cell survival, metabolism and 
      proliferation of the cells. However, overwhelmingly increasing scientific 
      evidence has added a new layer of intricacy to already complicated and versatile 
      signaling pathway of mTOR. Deregulation of spatio-temporally controlled 
      mTOR-driven pathway played contributory role in breast cancer development and 
      progression. Pharmacologists and molecular biologists have specifically 
      emphasized on the identification and development of mTOR-pathway inhibitors. In 
      this chapter we have attempted to provide an overview of the most recent findings 
      related to therapeutic targeting of mTOR-associated mTORC1 and mTORC2 in breast 
      cancer. We have also comprehensively summarized regulation of mTOR and its 
      partners by microRNAs in breast cancer.
FAU - Butt, Ghazala
AU  - Butt G
AD  - Department of Botany, GCU, Lahore, Pakistan. dr.ghazalayasmeen@gcu.edu.pk.
FAU - Shahwar, Durray
AU  - Shahwar D
AD  - Lahore College for Women University, Lahore, Pakistan.
FAU - Qureshi, Muhammad Zahid
AU  - Qureshi MZ
AD  - Department of Chemistry, GCU, Lahore, Pakistan.
FAU - Attar, Rukset
AU  - Attar R
AD  - Department of Obstetrics and Gynecology, Faculty of Medicine, Yeditepe 
      University, Istanbul, Turkey. ruksetattar@hotmail.com.
FAU - Akram, Misbah
AU  - Akram M
AD  - Department of Bioinformatics and Biotechnology, International Islamic University, 
      Islamabad, Pakistan.
FAU - Birinci, Yelda
AU  - Birinci Y
AD  - Faculty of Engineering and Natural Sciences, Sabanci University, Istanbul, 
      Turkey.
FAU - Karatoprak, Gokce Seker
AU  - Karatoprak GS
AD  - Department of Pharmacognosy, Faculty of Pharmacy, Erciyes University, Kayseri, 
      Turkey.
FAU - Gasparri, Maria Luisa
AU  - Gasparri ML
AD  - Department of Gynecology and Obstetrics, University Hospital of Bern and 
      University of Bern, Bern, Switzerland.
AD  - Department of Gynecology and Obstetrics, "Sapienza" University of Rome, Rome, 
      Italy.
AD  - Surgical and Medical Department of Translational Medicine, "Sapienza" University 
      of Rome, Rome, Italy.
FAU - Farooqi, Ammad Ahmad
AU  - Farooqi AA
AD  - Laboratory for Translational Oncology and Personalized Medicine, RLMC, Lahore, 
      Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (MicroRNAs)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 1)
RN  - EC 2.7.11.1 (Mechanistic Target of Rapamycin Complex 2)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Breast Neoplasms/*drug therapy
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Mechanistic Target of Rapamycin Complex 1/*metabolism
MH  - Mechanistic Target of Rapamycin Complex 2/*metabolism
MH  - MicroRNAs/genetics
MH  - Molecular Targeted Therapy
MH  - Neoplasm Metastasis
MH  - TOR Serine-Threonine Kinases/*metabolism
OTO - NOTNLM
OT  - Apoptosis
OT  - Signaling
OT  - Therapy
OT  - mTOR
EDAT- 2019/08/29 06:00
MHDA- 2019/09/17 06:00
CRDT- 2019/08/29 06:00
PHST- 2019/08/29 06:00 [entrez]
PHST- 2019/08/29 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
AID - 10.1007/978-3-030-20301-6_15 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2019;1152:283-292. doi: 10.1007/978-3-030-20301-6_15.